Introduction
Research peptides targeting the growth hormone axis fall into two primary mechanistic classes: GHRPs (Growth Hormone-Releasing Peptides) and GHRHs (Growth Hormone-Releasing Hormones). While both classes ultimately stimulate GH release from the pituitary, they do so through completely different receptors with different kinetic profiles and downstream effects. Understanding this distinction is essential for GH axis research design.
GHRHs: The Hypothalamic Signal
Growth hormone-releasing hormones (GHRHs) are analogues of the endogenous hypothalamic hormone GHRH, which acts on specific GHRH receptors in the anterior pituitary to stimulate GH synthesis and release. Native GHRH is a 44-amino acid peptide that is rapidly degraded by dipeptidyl peptidase IV (DPP-IV). Research GHRH analogues include Sermorelin (GHRH(1-29)), CJC-1295 Without DAC (stabilized GHRH(1-29) with 30-minute half-life), CJC-1295 With DAC (albumin-binding variant with 6-8 day half-life), and Tesamorelin (full-length GHRH(1-44) with N-terminal modification).
GHRPs: The Ghrelin Mimetics
Growth hormone-releasing peptides (GHRPs) are synthetic peptides that act through the ghrelin receptor (GHS-R1a) — a completely different receptor from the GHRH receptor. GHRPs mimic the action of ghrelin, the natural GHS-R1a ligand. Research GHRPs include GHRP-6, GHRP-2, Ipamorelin, and Hexarelin, with progressively different potencies and selectivity profiles. GHRPs primarily increase the frequency of GH pulses from the pituitary.
Different Mechanisms, Complementary Effects
GHRH receptor activation primarily amplifies the magnitude of GH pulses — each pulse releases more GH. GHS-R1a (GHRP) activation primarily increases the frequency of GH pulses — pulses occur more often. When both pathways are activated simultaneously (e.g., CJC-1295 + Ipamorelin), the result is both increased pulse magnitude and frequency, producing synergistic GH release that exceeds either compound alone. This complementary relationship explains why GHRH + GHRP combinations are so commonly used in research protocols.
Feedback Regulation Differences
GHRH-stimulated GH release remains subject to natural somatostatin feedback — rising GH levels trigger hypothalamic somatostatin release, which dampens further GH secretion. This maintains physiological regulation patterns. GHRP-mediated GH release also has feedback sensitivity but through somewhat different dynamics, as GHS-R1a activation has additional hypothalamic effects. The combination of GHRH + GHRP analogues appears to produce GH release that is regulated but enhanced compared to either alone.
Half-Life Comparison
GHRH analogues span a wide range of half-lives: Sermorelin approximately 10 to 20 minutes, CJC-1295 without DAC approximately 30 minutes, CJC-1295 with DAC approximately 6 to 8 days. Most GHRPs have short half-lives of 15 minutes to 2 hours, with Ipamorelin at approximately 2 hours being among the longer-acting. These half-life differences influence how research protocols using these compounds must be designed.
Selecting Between Classes for Research
For research studying acute GH pulses: combine a short-acting GHRH analogue with a GHRP. For sustained GH axis stimulation over days: use CJC-1295 with DAC alone or in combination. For clean GH-specific research with minimal cortisol or appetite confounds: Ipamorelin is the preferred GHRP. For potent GH release as a primary endpoint: GHRP-2 or Hexarelin. For cardiac research alongside GH effects: Hexarelin specifically.
Conclusion
GHRHs and GHRPs are mechanistically complementary — not competing — classes of GH axis research peptides. GHRHs amplify GH pulse magnitude through pituitary GHRH receptors while GHRPs increase pulse frequency through ghrelin receptors. Their combination produces synergistic GH release that forms the basis of the most commonly used GH axis research protocols.